Photo

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Photo

Berlusconi's women

A look at the women linked to former Italian Prime Minister Silvio Berlusconi.  Slideshow 

Photo

Harvesting tobacco

With the increasing health concerns with smoking in the U.S., traditional tobacco farmers sell their crop to growing markets outside the country.  Slideshow 

Sponsored Links

Merck revenues miss mark as diabetes, arthritis drugs lag

Related Topics

A general view shows the Merck facility in Rahway, New Jersey November 28, 2005.

Credit: Reuters

Tue Jul 30, 2013 9:51am EDT

(Reuters) - Merck & Co Inc's quarterly revenue fell short of Wall Street expectations as the stronger dollar cut sales of its consumer and animal health products and hurt results for prescription drugs, including diabetes treatment Januvia.

The second-biggest U.S. drugmaker said on Tuesday it earned $906 million, or 30 cents per share, in the second quarter. That compared with $1.79 billion, or 58 cents per share, in the year-earlier period.

Excluding special items, Merck earned 84 cents per share. Analysts, on average, expected 83 cents per share.

Global company revenue fell 11 percent to $11.01 billion, hurt by generic competition for its Singulair asthma drug, which lost U.S. patent protection a year ago. Wall Street expected company revenue of $11.22 billion.

Revenue would have fallen 8 percent if not for the stronger dollar, which lowers the value of sales in overseas markets.

Sales of Januvia, which has been one of Merck's fastest-growing drugs, rose 1 percent to $1.07 billion, but would have risen 7 percent if not for the stronger U.S. greenback.

(Reporting by Ransdell Pierson; Editing by Gerald E. McCormick and Jeffrey Benkoe)

 
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.